In the study of Wang et al., the indel mutation rate (78%) of ARID1A in MSI gastric cancer is comparable to that of TGFBR2 in MSI colon cancer, a well-established and functionally validated driver gene inactivated by MSI [25]. This evidence concerns the gene ARID1A and gastric cancer.